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Abstract
Background: Using guinea pig tracheal preparations, we have recently shown that endogenous arginase
activity attenuates inhibitory nonadrenergic noncholinergic (iNANC) nerve-mediated airway smooth
muscle relaxation by reducing nitric oxide (NO) production – due to competition with neuronal NO-
synthase (nNOS) for the common substrate, L-arginine. Furthermore, in a guinea pig model of allergic
asthma, airway arginase activity is markedly increased after the early asthmatic reaction (EAR), leading to
deficiency of agonist-induced, epithelium-derived NO and subsequent airway hyperreactivity.
In this study, we investigated whether increased arginase activity after the EAR affects iNANC nerve-
derived NO production and airway smooth muscle relaxation.
Methods: Electrical field stimulation (EFS; 150 mA, 4 ms, 4 s, 0.5 – 16 Hz)-induced relaxation was
measured in tracheal open-ring preparations precontracted to 30% with histamine in the presence of 1
µM atropine and 3 µM indomethacin. The contribution of NO to EFS-induced relaxation was assessed by
the nonselective NOS inhibitor Nω-nitro-L-arginine (L-NNA, 100 µM), while the involvement of arginase
activity in the regulation of EFS-induced NO production and relaxation was investigated by the effect of
the specific arginase inhibitor Nω-hydroxy-nor-L-arginine (nor-NOHA, 10 µM). Furthermore, the role of
substrate availability to nNOS was measured in the presence of exogenous L-arginine (5.0 mM).
Results: At 6 h after ovalbumin-challenge (after the EAR), EFS-induced relaxation (ranging from 3.2 ± 1.1%
at 0.5 Hz to 58.5 ± 2.2% at 16 Hz) was significantly decreased compared to unchallenged controls (7.1 ±
0.8% to 75.8 ± 0.7%; P < 0.05 all). In contrast to unchallenged controls, the NOS inhibitor L-NNA did not
affect EFS-induced relaxation after allergen challenge, indicating that NO deficiency underlies the impaired
relaxation. Remarkably, the specific arginase inhibitor nor-NOHA normalized the impaired relaxation to
unchallenged control (P < 0.05 all), which effect was inhibited by L-NNA (P < 0.01 all). Moreover, the effect
of nor-NOHA was mimicked by exogenous L-arginine.
Conclusion: The results clearly demonstrate that increased arginase activity after the allergen-induced
EAR contributes to a deficiency of iNANC nerve-derived NO and decreased airway smooth muscle
relaxation, presumably via increased substrate competition with nNOS.
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Background
Nitric oxide (NO) is an important endogenous bron-
chodilator and is generated by a family of NO synthase
(NOS) isoforms that utilize the semi-essential amino acid
L-arginine, oxygen and NADPH as substrates to produce
NO and L-citrulline [1]. In the airways, constitutive NOS
(cNOS) isoforms – neuronal (nNOS) and endothelial
NOS (eNOS) – are mainly expressed in inhibitory non-
adrenergic noncholinergic (iNANC) neurons (nNOS),
endothelium (eNOS) and epithelium (nNOS and eNOS),
whereas inducible NOS (iNOS), which is induced by
proinflammatory cytokines during airway inflammation,
is mainly expressed in macrophages and epithelial cells
[2].
Both in animal models and in patients it has been demon-
strated that a deficiency of cNOS-derived NO is impor-
tantly involved in the development of airway
hyperreactivity in allergic asthma [3-9]. Recent studies
have indicated that alterations in L-arginine homeostasis
play a major role in allergen-induced NO deficiency and
airway hyperreactivity [10]. Thus, in a guinea pig model of
allergic asthma we have demonstrated that a limitation of
L-arginine to NOS underlies the allergen-induced NO-
deficiency observed after the early asthmatic reaction
(EAR) [11].
One mechanism that may be of particular importance in
relation to reduced bioavailability of L-arginine in the air-
ways is increased activity of arginase, which hydrolyzes L-
arginine into L-ornithine and urea [10]. Arginase is
expressed in the airways [12] and has shown to be func-
tionally involved in the regulation of airway responsive-
ness to methacholine by competition with cNOS for the
common substrate, L-arginine [13]. In a guinea pig model
of allergic asthma, we have demonstrated that arginase
activity in the airways is markedly increased after the aller-
gen-induced EAR, thereby contributing to the observed
NO-deficiency and subsequent airway hyperreactivity to
methacholine [14]. Remarkably, inhibition of arginase
activity by the specific inhibitor Nω-hydroxy-nor-L-
arginine (nor-NOHA) completely reversed the airway
hyperreactivity to the level of unchallenged controls by
restoring NO production [14]. In line with these observa-
tions, increased arginase expression and/or activity have
similarly been found in murine models of allergic asthma
[15] and in asthmatic patients [15,16].
In a guinea pig model of asthma, a deficiency of cNOS-
derived NO has previously also been implicated in
reduced activity of the iNANC nervous system in the air-
ways [17], which is the most effective bronchodilating
neural pathway in both guinea pig and human airways
[18-22]. Moreover, in guinea pig tracheal preparations we
have recently demonstrated that endogenous arginase
activity attenuates iNANC nerve-mediated NO produc-
tion and airway smooth muscle relaxation under basal
conditions, via competition with nNOS for L-arginine
[23]. Therefore, in the present study we investigated the
hypothesis that increased arginase activity in the airways
induced by allergen challenge may also cause a deficiency
of iNANC nerve-mediated NO and reduced airway
smooth relaxation.
Methods
Animals
Male specified pathogen free Dunkin Hartley guinea pigs
(Harlan Hillcrest, UK), weighing 500 – 800 g, were used.
The animals were group-housed in individual cages in cli-
mate-controlled animal quarters and given water and
food ad libitum, while a 12-h on/12-h off light cycle was
maintained. The animals were IgE-sensitized to ovalbu-
min with Al(OH)3 as adjuvant as described [24] and used
experimentally 4 to 6 weeks later.
All protocols described in this study were approved by the
University of Groningen Committee for Animal Experi-
mentation.
Allergen provocation
Allergen provocations were performed by inhalation of an
aerosolized solution of 0.5 mg/ml ovalbumin in saline as
described [25]. Allergen inhalations were discontinued
when the first signs of respiratory distress were observed.
The animals were sacrificed 6 h after allergen provocation,
i.e. after the EAR [26]. Nonchallenged animals served as
controls.
Tissue preparation
Guinea pigs were sacrificed by a sharp blow on the head
followed by rapid exsanguination. The trachea was
removed and prepared free of serosal connective tissue in
a Krebs-Henseleit buffer solution of 37°C, gassed with
95% O2 and 5% CO2. The composition of the Krebs-
Henseleit-solution in mM was: NaCl 117.50; KCl 5.60;
MgSO4 1.18; CaCl2 2.50; NaH2PO4 1.28; NaHCO3 25.0
and D-glucose 5.50; pH 7.4. Twelve single proximal tra-
cheal open-ring preparations were mounted for isotonic
recording (0.3 g preload) between two parallel platinum
point-electrodes in 20 ml organ baths containing gassed
Krebs-Henseleit solution and indomethacin (3 µM) to
eliminate any influence of prostanoids.
Electrical field stimulation-induced relaxation 
experiments
After 30 min equilibration, tracheal preparations were
relaxed with isoprenaline (0.1 µM) to establish basal tone.
No difference in basal tone was observed in the prepara-
tions obtained from allergen challenged animals as com-
pared to unchallenged animals. After thorough washout,Respiratory Research 2006, 7:6 http://respiratory-research.com/content/7/1/6
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maximal contraction to histamine was determined with
cumulative additions of the agonist (0.1, 1, 10 and 100
µM). After washout, the preparations were precontracted
with histamine to 30% of maximal histamine-induced
tone in the presence of atropine (1 µM) to prevent electri-
cal field stimulation (EFS)-induced cholinergic airway
contraction. On the plateau, biphasic EFS (150 mA, 4 ms,
4 s, 0.5 – 16 Hz) was applied and one frequency-response
curve (0.5 – 16 Hz in doubling steps) per preparation was
recorded. When used, the nonselective NOS inhibitor Nω-
nitro-L-arginine (L-NNA; 100 µM), the specific arginase
inhibitor nor-NOHA (10 µM), a combination of the two
inhibitors, or L-arginine (5.0 mM) were applied 30 min
prior to histamine-administration. In line with previous
observations [3,23], neither the NOS inhibitor, nor the
arginase inhibitor and L-arginine affected agonist-induced
contraction in the open-ring preparations. After the final
EFS-induced relaxation, followed by washout, isoprena-
line (10 µM) was added to re-establish basal tone. All
measurements were performed in triplicate.
Data analysis
All relaxations were estimated as peak height of the EFS-
induced response, and were expressed as a percentage of
maximal relaxation, as established in the presence of iso-
prenaline. The contribution of NO to the EFS-induced
relaxation was determined by the effect of the NOS inhib-
itor L-NNA. Similarly, the role of arginase activity in the
modulation of EFS-induced airway relaxation was deter-
mined by the effect of the arginase inhibitor nor-NOHA.
The role of substrate availability in EFS-induced airway
relaxation was assessed by measuring the response in the
presence of exogenous L-arginine.
All data are expressed as means ± s.e.m. of n experiments.
Statistical significance of differences was evaluated using a
paired or unpaired two-tailed Student's t-test as appropri-
ate, and significance was accepted when P < 0.05.
Chemicals
Ovalbumin (grade III), aluminium hydroxide, histamine
dihydrochloride, indomethacin, atropine sulphate, L-
arginine hydrochloride, Nω-nitro-L-arginine and (-)-iso-
prenaline hydrochloride were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). Nω-hydroxy-nor-L-
arginine was kindly provided by Dr J.-L. Boucher (Univer-
sité Paris V, France).
Results
In line with our previous study [23], EFS (0.5 – 16 Hz)
induced a frequency-dependent relaxation of histamine-
induced tone of tracheal open-ring preparations from
unchallenged guinea pigs, ranging from 7.1 ± 0.8% at 0.5
Hz to 75.8 ± 0.7% at 16 Hz. Incubation with the NOS
inhibitor L-NNA (100 µM) caused a marked attenuation
of the EFS-induced relaxation at 0.5 to 8 Hz, particularly
at the lower frequencies (P < 0.05 all; Fig. 1).
At 6 h after ovalbumin-challenge (after the EAR), EFS-
induced relaxations were significantly decreased at all fre-
quencies as compared to unchallenged controls (values
ranging from 3.2 ± 1.1% at 0.5 Hz to 58.5 ± 2.2% at 16
Hz; P < 0.05 all), to a similar extent as observed in L-NNA-
treated preparations from unchallenged animals (Fig. 1).
In contrast to tracheal preparations from unchallenged
animals, L-NNA did not affect EFS-induced relaxations of
the allergen-challenged preparations (Fig. 1), indicating
deficiency of nNOS-derived NO after the allergen-induced
EAR.
Interestingly, the impaired relaxations after allergen chal-
lenge were markedly increased by the specific arginase
inhibitor nor-NOHA (10 µM) at all, but particularly the
lower, frequencies (P < 0.05 all; Fig. 2). At 0.5 to 8 Hz, the
iNANC relaxations were completely normalized to the
level of unchallenged controls. The effect of the arginase
inhibitor was reversed after coincubation with L-NNA at
all frequencies (P < 0.01 all; Fig. 2).
Similar to nor-NOHA, administration of exogenous L-
arginine (5.0 mM) reversed the impaired relaxations after
the EAR, also particularly at the lower frequencies (Fig. 3).
iNANC nerve-induced airway smooth muscle relaxation is  impaired after allergen challenge due to deficiency of nNOS- derived NO Figure 1
iNANC nerve-induced airway smooth muscle relaxa-
tion is impaired after allergen challenge due to defi-
ciency of nNOS-derived NO. Electrical field stimulation-
induced relaxation of precontracted tracheal open-ring prep-
arations obtained from unchallenged and from OA-chal-
lenged guinea pigs in the absence and presence of the NOS 
inhibitor L-NNA (100 µM). Results are means ± s.e.m. of 7 
experiments for each condition. *P < 0.05 and **P < 0.01 
compared to unchallenged control, n.s. = non significant.Respiratory Research 2006, 7:6 http://respiratory-research.com/content/7/1/6
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Discussion
In both guinea pigs and humans, the iNANC nervous sys-
tem is the most effective bronchodilating neural pathway
of the airways, in which NO and vasoactive intestinal
polypeptide act as neurotransmitters [18-22,27,28].
Recently, we have demonstrated that endogenous argin-
ase activity is functionally involved in the regulation of
iNANC nerve activity in the airway wall [23]. Thus, using
guinea pig tracheal preparations, it was shown that argin-
ase attenuates iNANC nerve-mediated airway smooth
muscle relaxation specifically by inhibition of NO gener-
ation, presumably by limiting L-arginine availability to
nNOS [23]. In a guinea pig model of allergic asthma, we
have now shown that increased arginase activity, which is
present in the airways after the allergen-induced EAR [14],
may cause a considerably reduced iNANC relaxation of
airway smooth muscle, due to deficiency of NO produc-
tion. This reduced iNANC activity and deficiency of neu-
ronal NO may contribute to the observed airway
hyperreactivity in allergic asthma.
In line with previous studies [18,23], it was demonstrated
that the NOS inhibitor L-NNA inhibited EFS-induced
iNANC relaxations of guinea pig tracheal preparations.
This inhibition was most pronounced at the lower fre-
quencies (0.5 to 4 Hz), indicating a prominent role of
nNOS-derived NO at these frequencies. Remarkably,
allergen challenge resulted in reduced iNANC relaxations
to the level of control preparations in the presence of L-
NNA. Moreover, the reduced relaxations after allergen-
challenge were not affected by L-NNA, indicating that a
deficiency of nNOS-derived NO underlies the impaired
iNANC relaxations.
Inhibition of arginase activity restored the impaired
iNANC relaxations particularly at lower frequencies, indi-
cating that increased arginase activity strongly restricts
iNANC nerve-mediated airway smooth muscle relaxation.
The increased relaxation after arginase inhibition was
completely reversed by L-NNA, demonstrating that argin-
ase activity attenuates iNANC nerve-mediated airway
smooth muscle relaxation by limiting NO production.
Since arginase activity in guinea pig airway preparations is
markedly increased after the EAR [14], it seems obvious
that increased competition with nNOS for L-arginine
underlies the deficiency of nNOS-derived NO and subse-
quently impaired relaxations. That a limitation of endog-
enous L-arginine is involved indeed, was indicated by the
effect of exogenous L-arginine, which, as nor-NOHA, nor-
malized iNANC relaxations at the lower frequencies to the
level of unchallenged controls. Using perfused tracheal
preparations, we have previously demonstrated that L-
arginine limitation due to increased arginase activity after
the EAR also contributes to deficiency of agonist-induced,
epithelium-derived NO and subsequent airway hyperreac-
tivity [3,11,14]. Taken together, increased arginase activity
upon allergen challenge causes a deficiency of both neural
and nonneural cNOS-derived NO in the airways, which
strongly contributes to the development of allergen-
induced airway hyperreactivity after the EAR.
Although arginase is classically considered to be an
enzyme of the urea cycle in the liver, it also occurs in many
extrahepatic cells and tissues [29], where it may regulate
NO synthesis by limiting the availability of intracellular L-
arginine to NOS [12,29-31]. Two distinct isoforms of argi-
nase have been identified: the cytosolic enzyme arginase
I, highly expressed in the liver, and the mitochondrial
arginase II, mainly expressed in extrahepatic tissues [29].
Both arginase isoforms are constitutively expressed in the
airways, particularly in the bronchial epithelium and in
fibroblasts from peribronchial connective tissue [12]. It
has been demonstrated that the Th2 cytokines IL-4 and IL-
13 increase arginase activity and expression of both iso-
forms in mouse lung [15] and in rat airway fibroblasts
[32]. Increased arginase expression and activity was also
found in a murine model of allergic asthma, both after
challenge with ovalbumin and with Aspergillus fumigatus.
Moreover, among the 291 common genes induced by
these allergens, arginase I and II belonged to the most pre-
Role of arginase and NO in impaired iNANC nerve-induced  relaxation of guinea pig tracheal smooth muscle after aller- gen-challenge Figure 2
Role of arginase and NO in impaired iNANC nerve-
induced relaxation of guinea pig tracheal smooth 
muscle after allergen-challenge. Electrical field stimula-
tion-induced relaxation of precontracted tracheal open-ring 
preparations obtained from unchallenged and from OA-chal-
lenged guinea pigs in the absence and presence of the argin-
ase inhibitor nor-NOHA (10 µM), with or without the NOS 
inhibitor L-NNA (100 µM). Results are means ± s.e.m. of 7 
experiments for each condition. *P < 0.05 and **P < 0.01 
compared to unchallenged control, †P < 0.05 and ‡P < 0.01 
compared to OA-challenged control, #P < 0.01 compared to 
nor-NOHA-treated.Respiratory Research 2006, 7:6 http://respiratory-research.com/content/7/1/6
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dominantly overexpressed genes [15]. Furthermore, in
sensitized mice challenged with Schistosoma mansoni eggs
increased arginase I gene expression was observed in wild
type and Th2 polarized mice, but not in Th1 polarized
animals [33].
The importance of arginase activity in the pathophysiol-
ogy of allergic asthma has been indicated by the finding
that arginase I protein expression is increased in bronchial
alveolar lavage cells of asthmatic patients [15]. In addi-
tion, enhanced mRNA expression of arginase I was
observed in the airway epithelium and in inflammatory
cells in bronchial biopsies of these patients [15]. Morris
and coworkers demonstrated that while plasma L-
arginine levels are decreased in asthmatic patients during
exacerbation, serum arginase activity is markedly
increased [16], thus supporting the hypothesis that a dis-
turbed L-arginine homeostasis due to increased arginase
activity underlies airway hyperreactivity in allergic asthma
[10].
A deficiency of iNANC nerve-derived NO has previously
also been demonstrated by Miura et al. in sensitized
guinea pigs airways at 24 h after the last of three consecu-
tive daily ovalbumin-challenges. This could be restored in
part by incubation with superoxide dismutase, indicating
that scavenging of NO by superoxide could be involved
[17]. In the present study, we demonstrated that NO-
induced iNANC relaxation is already impaired at 6 h after
single allergen-challenge. Using the same model, we have
previously found that superoxide anions are not involved
in the deficiency of nonneural, agonist-induced cNOS-
derived NO at 6 h after single challenge [34], making its
possible role in the reduced iNANC activity at this time-
point unlikely.
In addition to arginase, downregulation of nNOS could
also be involved in reduced iNANC activity. However, an
effect of allergen challenge on the expression of nNOS was
not found by Miura and coworkers [17]. Moreover, in the
present study we demonstrated that increasing the availa-
bility of L-arginine – by arginase inhibition or exogenous
addition of the amino acid – reversed impaired iNANC
nerve-mediated airway smooth muscle relaxations, indi-
cating that downregulation of nNOS does not underlie
the impaired iNANC activity. This is line with previous
studies, showing that nNOS expression is not affected by
(repeated) allergen challenge [8,35,36], although some
reduced expression of nNOS has been observed in one
study [9].
Another mechanism which might contribute to L-arginine
limitation after the EAR is impaired uptake of L-arginine
caused by polycations. It has been reported that the major
basic protein analogue poly-L-arginine inhibits L-arginine
uptake [37] and causes airway hyperreactivity to metha-
choline in perfused guinea pig tracheal preparations by
causing a deficiency of agonist-induced NO [38]. We have
also demonstrated that endogenous (eosinophil-derived)
polycations may be involved in allergen-induced NO defi-
ciency and airway hyperreactivity after the EAR [39]. Thus,
incubation with the polyanion heparin – acting as a scav-
enger of polycations – restored the production of NO and
normalized airway reactivity to unchallenged control, pre-
sumably by restoration of cellular L-arginine uptake
through cationic amino acid transporters [39].
Several studies have indicated that NO is the major neuro-
transmitter in iNANC nerve-mediated relaxations of
guinea pig airways at lower frequencies [20,23,40,41],
while EFS-induced relaxations at the higher frequencies
may involve vasoactive intestinal polypeptide [20,41] as
well as sympathetic nerve-derived noradrenaline [42].
This is in line with our observation that iNANC-mediated
relaxations are more sensitive to L-NNA at the lower fre-
quencies and very well explains why nor-NOHA is most
effective at these frequencies.
A deficiency of iNANC nerve-derived NO has recently also
been implicated in the pathophysiology of cystic fibrosis.
Thus, in a mouse model of cystic fibrosis, impaired EFS-
induced NO mediated airway smooth muscle relaxation
Role of L-arginine availability in impaired iNANC nerve- induced relaxation of guinea pig tracheal smooth muscle after  allergen-challenge Figure 3
Role of L-arginine availability in impaired iNANC 
nerve-induced relaxation of guinea pig tracheal 
smooth muscle after allergen-challenge. Electrical field 
stimulation-induced relaxation of precontracted tracheal 
open-ring preparations obtained from unchallenged and from 
OA-challenged guinea pigs in the absence and presence of L-
arginine (5.0 mM). Results are means ± s.e.m. of 4 (OA-chal-
lenged) to 7 (unchallenged) experiments. *P < 0.05 and **P < 
0.01 compared to unchallenged control, †P < 0.05 compared 
to OA-challenged control.Respiratory Research 2006, 7:6 http://respiratory-research.com/content/7/1/6
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was observed, which was reversed by L-arginine [43].
Moreover, it has recently been shown that arginase activity
is increased in sputum obtained from patients with cystic
fibrosis as compared to healthy controls [44]. In addition,
a negative correlation between sputum arginase activity
and levels of exhaled NO as well as FEV1 was observed in
these patients [44]. A role for arginase by restricting the L-
arginine availability to nNOS in iNANC nerves has also
been proposed in the pathophysiology of erectile dysfunc-
tion [45]. In support, increased expression and activity of
arginase II contributing to reduced iNANC nerve-derived
NO production has been demonstrated in diabetic caver-
nosal tissue [46]. Moreover, neuronal arginase has shown
to be involved in gastrointestinal motility disorders, by
reducing nNOS-mediated iNANC relaxation in the inter-
nal anal sphincter [47].
Conclusion
Using a guinea pig model of allergic asthma we have
established that iNANC relaxations are markedly reduced
after the allergen-induced EAR, due to a deficiency of
nNOS-derived NO. Increased arginase activity is a major
cause of the NO deficiency and impaired iNANC relaxa-
tion, presumably via increased substrate competition with
nNOS.
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